- JP-listed companies
- OncoTherapy Science, Inc.
- Balance sheet
OncoTherapy Science, Inc. (4564) Balance sheet
Market cap
¥6.4B
P/E ratio
OncoTherapy Science develops cancer treatments using genetic research, including targeted drugs, immunotherapies, and precision medicine testing for personalized cancer care.
| 2014/03 | 2015/03 | 2016/03 | 2017/03 | 2018/03 | 2019/03 | 2020/03 | 2021/03 | 2022/03 | 2023/03 | 2024/03 | 2025/03 | |
| Cash and cash equivalents | - | 16,072 | 13,070 | 10,073 | 6,740 | 4,858 | 4,714 | 2,899 | 1,837 | 1,118 | 528 | 834 |
| Total cash & short-term investments | - | 16,072 | 13,070 | 10,073 | 6,740 | 4,858 | 4,714 | 2,899 | 1,837 | 1,118 | 528 | 834 |
| Total current assets | - | 16,237 | 13,288 | 10,289 | 7,034 | 5,055 | 4,878 | 3,194 | 2,601 | 1,422 | 818 | 1,106 |
| Property, plant and equipment, net | - | 254 | 277 | 220 | 582 | 201 | 113 | 95 | 0 | - | - | - |
| Marketable securities, non-current | - | - | - | - | - | - | - | - | - | - | - | - |
| Total non-current assets | - | 372 | 375 | 304 | 987 | 312 | 210 | 174 | 85 | 89 | 50 | 50 |
| Total assets | - | 16,608 | 13,663 | 10,593 | 8,022 | 5,367 | 5,088 | 3,368 | 2,685 | 1,511 | 867 | 1,155 |
| Total current liabilities | - | 338 | 371 | 370 | 306 | 368 | 243 | 195 | 605 | 609 | 360 | 328 |
| Total non-current liabilities | - | 207 | 177 | 119 | 136 | 129 | 117 | 96 | 100 | 47 | 154 | 98 |
| Total liabilities | - | 545 | 549 | 488 | 442 | 497 | 360 | 291 | 705 | 656 | 514 | 426 |
| Retained earnings | - | -5,738 | -8,526 | -11,528 | -14,379 | -17,314 | -19,553 | -21,115 | -23,686 | -24,805 | -26,093 | -26,908 |
| Stockholders' equity | 17,783 | 16,064 | 13,115 | 10,104 | 7,580 | 4,870 | 4,728 | 3,077 | 1,980 | 855 | 354 | 729 |